Liraglutide treatment was initiated simultaneously to corticosterone and our data supports that such an approach should be considered when handling patients with susceptibility towards steroid-induced diabetes, like subjects with a priori known insulin resistance [31], low insulin secretion capacity [12,32], genetic predisposition [33], or in patients with obesity [34]. The gene discussed is INS; the disease is Obesity.